title: Time to refocus on HSV interventions for HIV prevention?
authors: Clare
authors: C
authors: Tanton
authors: Laith J
authors: LJ
authors: Abu-Raddad
authors: Helen A
authors: HA
authors: Weiss
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification* / Q000378:metabolism*; D006558:Herpes Genitalis / Q000188:drug therapy*; D006561:Herpes Simplex / Q000150:complications* / Q000188:drug therapy*; D018258:Herpesvirus 2, Human / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood*; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir